Twin Securities adds St. Jude Medical (STJ) to its portfolio

St. Jude Medical (STJ) : Twin Securities added new position in St. Jude Medical during the most recent quarter end. The investment management firm now holds 737,256 shares of St. Jude Medical which is valued at $57,852,478 , the company said in a statement filed on Nov 14, 2016 with the SEC.St. Jude Medical makes up approximately 12.23% of Twin Securities’s portfolio.

Other Hedge Funds, Including , Manufacturers Life Insurance Company The reduced its stake in STJ by selling 1,626 shares or 0.57% in the most recent quarter. The Hedge Fund company now holds 281,432 shares of STJ which is valued at $22,345,701. St. Jude Medical makes up approx 0.03% of Manufacturers Life Insurance Company The’s portfolio.Deprince Race Zollo Inc reduced its stake in STJ by selling 69,479 shares or 12.95% in the most recent quarter. The Hedge Fund company now holds 467,061 shares of STJ which is valued at $36,169,204. St. Jude Medical makes up approx 0.79% of Deprince Race Zollo Inc’s portfolio.First National Trust Co reduced its stake in STJ by selling 2,167 shares or 17.28% in the most recent quarter. The Hedge Fund company now holds 10,370 shares of STJ which is valued at $805,127. St. Jude Medical makes up approx 0.13% of First National Trust Co’s portfolio.Shell Asset Management Co reduced its stake in STJ by selling 2,115 shares or 9.35% in the most recent quarter. The Hedge Fund company now holds 20,504 shares of STJ which is valued at $1,596,031. St. Jude Medical makes up approx 0.04% of Shell Asset Management Co’s portfolio.

St. Jude Medical closed down -0.2 points or -0.25% at $80.02 with 23,00,482 shares getting traded on Monday. Post opening the session at $80.07, the shares hit an intraday low of $79.87 and an intraday high of $80.27 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, St. Jude Medical reported $0.99 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Oct 19, 2016. Analyst had a consensus of $1.01. The company had revenue of $1499.00 million for the quarter, compared to analysts expectations of $1498.08 million. The company’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.97 EPS.

St. Jude Medical Inc. develops manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management cardiovascular and atrial fibrillation therapy areas and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems bradycardia pacemaker systems atrial fibrillation (AF) products (electrophysiology introducers and catheters advanced cardiac mapping navigation and recording systems and ablation systems) vascular products (vascular closure products pressure measurement guidewires optical coherence tomography (OCT) imaging products heart failure monitoring device and other vascular accessories) structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

St. Jude Medical - Is it time to Sell?

Top Brokerage Firms are advising their investors on St. Jude Medical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.